{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,28]],"date-time":"2026-05-28T22:02:33Z","timestamp":1780005753021,"version":"3.53.1"},"reference-count":19,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2026,2,1]],"date-time":"2026-02-01T00:00:00Z","timestamp":1769904000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,2,1]],"date-time":"2026-02-01T00:00:00Z","timestamp":1769904000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,5,30]],"date-time":"2025-05-30T00:00:00Z","timestamp":1748563200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["international-journal-of-gynecological-cancer.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["International Journal of Gynecological Cancer"],"published-print":{"date-parts":[[2026,2]]},"DOI":"10.1016\/j.ijgc.2025.101950","type":"journal-article","created":{"date-parts":[[2025,5,24]],"date-time":"2025-05-24T10:56:03Z","timestamp":1748084163000},"page":"101950","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Trabectedin maintenance therapy after liposomal doxorubicin plus trabectedin combination in patients with relapsed ovarian cancer: the randomized, phase II TRAMANT study"],"prefix":"10.1016","volume":"36","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-8025-581X","authenticated-orcid":false,"given":"Giuseppa","family":"Scandurra","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giuseppe","family":"Scibilia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0446-6436","authenticated-orcid":false,"given":"Valentina","family":"Lombardo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antonella","family":"Savarese","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1158-4630","authenticated-orcid":false,"given":"Carmine","family":"De Angelis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Simona","family":"Scalone","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elena","family":"Geuna","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Valentina","family":"Tuninetti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giorgio","family":"Valabrega","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antonio","family":"Ardizzoia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Claudio","family":"Zamagni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vanda","family":"Salutari","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9503-9041","authenticated-orcid":false,"given":"Giovanni","family":"Scambia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paolo","family":"Scollo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ijgc.2025.101950_bib1","series-title":"StatPearls","article-title":"Ovarian cancer","author":"Arora","year":"2023"},{"issue":"suppl 8","key":"10.1016\/j.ijgc.2025.101950_bib2","doi-asserted-by":"crossref","first-page":"viii51","DOI":"10.1093\/annonc\/mdx441","article-title":"Treatment of recurrent ovarian cancer","volume":"28","author":"Pignata","year":"2017","journal-title":"Ann Oncol"},{"issue":"1","key":"10.1016\/j.ijgc.2025.101950_bib3","doi-asserted-by":"crossref","first-page":"41","DOI":"10.3390\/cancers16010041","article-title":"MITO39: efficacy and tolerability of pegylated liposomal doxorubicin (PLD)-trabectedin in the treatment of relapsed ovarian cancer after maintenance therapy with PARP inhibitors-A multicenter Italian trial in ovarian cancer observational case-control study","volume":"16","author":"Turinetto","year":"2023","journal-title":"Cancers (Basel)"},{"issue":"12","key":"10.1016\/j.ijgc.2025.101950_bib4","doi-asserted-by":"crossref","first-page":"1147","DOI":"10.1080\/14737140.2017.1398088","article-title":"Optimizing treatment in recurrent epithelial ovarian cancer","volume":"17","author":"Corrado","year":"2017","journal-title":"Expert Rev Anticancer Ther"},{"issue":"suppl 24","key":"10.1016\/j.ijgc.2025.101950_bib5","doi-asserted-by":"crossref","first-page":"4609","DOI":"10.1002\/cncr.32500","article-title":"Treatment of recurrent epithelial ovarian cancer","volume":"125","author":"Pignata","year":"2019","journal-title":"Cancer"},{"issue":"2","key":"10.1016\/j.ijgc.2025.101950_bib6","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1016\/S1470-2045(20)30637-9","article-title":"Carboplatin-based doublet plus bevacizumab beyond progression versus carboplatin-based doublet alone in patients with platinum-sensitive ovarian cancer: a randomised, phase 3 trial","volume":"22","author":"Pignata","year":"2021","journal-title":"Lancet Oncol"},{"issue":"3","key":"10.1016\/j.ijgc.2025.101950_bib7","doi-asserted-by":"crossref","first-page":"366","DOI":"10.1016\/j.ctrv.2013.08.001","article-title":"Emerging treatment strategies in recurrent platinum-sensitive ovarian cancer: focus on trabectedin","volume":"40","author":"Poveda","year":"2014","journal-title":"Cancer Treat Rev"},{"issue":"4","key":"10.1016\/j.ijgc.2025.101950_bib8","doi-asserted-by":"crossref","first-page":"727","DOI":"10.1093\/annonc\/mdw663","article-title":"Fifth Ovarian Cancer Consensus Conference of the Gynecologic Cancer InterGroup: recurrent disease","volume":"28","author":"Wilson","year":"2017","journal-title":"Ann Oncol"},{"issue":"1","key":"10.1016\/j.ijgc.2025.101950_bib9","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1016\/j.ygyno.2004.03.047","article-title":"The role of topotecan for extending the platinum-free interval in recurrent ovarian cancer: an in vitro model","volume":"94","author":"Horowitz","year":"2004","journal-title":"Gynecol Oncol"},{"issue":"2","key":"10.1016\/j.ijgc.2025.101950_bib10","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1634\/theoncologist.4-2-87","article-title":"Extending the platinum-free interval in recurrent ovarian cancer: the role of topotecan in second-line chemotherapy","volume":"4","author":"Bookman","year":"1999","journal-title":"Oncologist"},{"issue":"2","key":"10.1016\/j.ijgc.2025.101950_bib11","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1136\/ijgc-00009577-200503000-00004","article-title":"Retrospective review: re-treatment of patients with ovarian cancer with carboplatin after platinum resistance","volume":"15","author":"See","year":"2005","journal-title":"Int J Gynecol Cancer"},{"issue":"4","key":"10.1016\/j.ijgc.2025.101950_bib12","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1016\/j.ejcsup.2007.12.003","article-title":"Management of partially platinum-sensitive relapsed ovarian cancer","volume":"6","author":"Kaye","year":"2008","journal-title":"Eur J Canc Suppl."},{"key":"10.1016\/j.ijgc.2025.101950_bib14","first-page":"viii1","article-title":"A randomized phase III study of trabectedin with pegylated liposomal doxorubicin (PLD) versus PLD in relapsed, recurrent ovarian cancer (OC)","volume":"19","author":"Monk","year":"2008","journal-title":"Ann Oncol"},{"issue":"19","key":"10.1016\/j.ijgc.2025.101950_bib15","doi-asserted-by":"crossref","first-page":"3107","DOI":"10.1200\/JCO.2009.25.4037","article-title":"Trabectedin plus pegylated liposomal doxorubicin in recurrent ovarian cancer","volume":"28","author":"Monk","year":"2010","journal-title":"J Clin Oncol"},{"issue":"1","key":"10.1016\/j.ijgc.2025.101950_bib16","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1093\/annonc\/mdq352","article-title":"Trabectedin plus pegylated liposomal doxorubicin in relapsed ovarian cancer: outcomes in the partially platinum-sensitive (platinum-free interval 6\u201312 months) subpopulation of OVA-301 phase III randomized trial","volume":"22","author":"Poveda","year":"2011","journal-title":"Ann Oncol"},{"issue":"2","key":"10.1016\/j.ijgc.2025.101950_bib17","doi-asserted-by":"crossref","first-page":"447","DOI":"10.1159\/000500411","article-title":"Maintenance with trabectedin in the treatment of platinum-sensitive recurrent ovarian cancer","volume":"12","author":"Guerra Al\u00eda","year":"2019","journal-title":"Case Rep Oncol"},{"issue":"1","key":"10.1016\/j.ijgc.2025.101950_bib18","doi-asserted-by":"crossref","first-page":"41","DOI":"10.19156\/cbn.2016.0008","article-title":"Case 2: Trabectedin as a maintenance therapy in a patient with recurrent ovarian cancer and BRCA1 germline mutation","volume":"4","author":"Greco","year":"2016","journal-title":"CBN"},{"issue":"25","key":"10.1016\/j.ijgc.2025.101950_bib19","doi-asserted-by":"crossref","first-page":"2416","DOI":"10.1056\/NEJMoa1911361","article-title":"Olaparib plus bevacizumab as first-line maintenance in ovarian cancer","volume":"381","author":"Ray-Coquard","year":"2019","journal-title":"N Engl J Med"},{"issue":"5","key":"10.1016\/j.ijgc.2025.101950_bib20","doi-asserted-by":"crossref","first-page":"932","DOI":"10.3390\/cancers16050932","article-title":"PARP inhibitors: strategic use and optimal management in ovarian cancer","volume":"16","author":"Hirschl","year":"2024","journal-title":"Cancers (Basel)"}],"container-title":["International Journal of Gynecological Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1048891X25010709?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1048891X25010709?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,5,28]],"date-time":"2026-05-28T21:19:57Z","timestamp":1780003197000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1048891X25010709"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2]]},"references-count":19,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2026,2]]}},"alternative-id":["S1048891X25010709"],"URL":"https:\/\/doi.org\/10.1016\/j.ijgc.2025.101950","relation":{},"ISSN":["1048-891X"],"issn-type":[{"value":"1048-891X","type":"print"}],"subject":[],"published":{"date-parts":[[2026,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Trabectedin maintenance therapy after liposomal doxorubicin plus trabectedin combination in patients with relapsed ovarian cancer: the randomized, phase II TRAMANT study","name":"articletitle","label":"Article Title"},{"value":"International Journal of Gynecological Cancer","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ijgc.2025.101950","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Authors. Published by Elsevier Inc. on behalf of European Society of Gynaecological Oncology and the International Gynecologic Cancer Society.","name":"copyright","label":"Copyright"}],"article-number":"101950"}}